The comprehensive white paper, “Artificial Intelligence in Drug Development: Navigating Emerging Regulatory Expectations and Enhancing Clinical Trials,” authored by Patrick Brady, PharmD, explores the transformative potential of AI and machine learning (ML) in clinical trials. This paper provides valuable insights into how global health authorities are shaping the regulatory framework and offers practical guidance on leveraging AI/ML to improve trial efficiency, design, and outcomes. The valuable learnings include:
Regulatory Insights: Understand the current regulatory landscape with insights from the FDA and EMA on the use of AI/ML in clinical trials.
Risk-Based Approaches: Learn how to implement risk management plans to mitigate potential risks and ensure the safety and reliability of AI/ML applications.
Strategic AI/ML Applications: Discover practical applications of AI/ML in clinical trials, including patient recruitment, dose optimization, and participant stratification.